Patent application number | Description | Published |
20080301056 | ONLINE PAYER AUTHENTICATION SERVICE - A payment authentication service authenticates the identity of a payer during online transactions. The authentication service of the present invention allows a card issuer to verify a cardholder's identity using a variety of authentication methods, such as the use of passwords. Also, the only system participant requiring a certificate is the issuing financial institution. One embodiment of the invention for authenticating the identity of a cardholder during an online transaction involves querying an access control server to determine if a cardholder is enrolled in the payment authentication service, requests a password from the cardholder, verifies the password, and notifies a merchant whether the cardholder's authenticity has been verified. In another aspect of the invention, a chip card and the authentication service independently generate cryptograms that must match in order for the service to verify that the correct chip card is being used by the cardholder. | 12-04-2008 |
20100057619 | ACCOUNT AUTHENTICATION SERVICE WITH CHIP CARD - A payment authentication service authenticates the identity of a payer during online transactions. The authentication service of the present invention allows a card issuer to verify a cardholder's identity using a variety of authentication methods, such as the use of passwords. Also, the only system participant requiring a certificate is the issuing financial institution. One embodiment of the invention for authenticating the identity of a cardholder during an online transaction involves querying an access control server to determine if a cardholder is enrolled in the payment authentication service, requests a password from the cardholder, verifies the password, and notifies a merchant whether the cardholder's authenticity has been verified. In another aspect of the invention, a chip card and the authentication service independently generate cryptograms that must match in order for the service to verify that the correct chip card is being used by the cardholder. | 03-04-2010 |
20100063895 | MOBILE ACCOUNT AUTHENTICATION SERVICE - A payment authentication service authenticates the identity of a payer during online transactions. The authentication service allows a card issuer to verify a cardholder's identity using a variety of authentication methods, such as with the use of tokens. Authenticating the identity of a cardholder during an online transaction involves querying an access control server to determine if a cardholder is enrolled in the payment authentication service, requesting a password from the cardholder, verifying the password, and notifying a merchant whether the cardholder's authenticity has been verified. Systems for implementing the authentication service in which a cardholder uses a mobile device capable of transmitting messages via the Internet are described. Systems for implementing the authentication service in which a cardholder uses a mobile device capable of transmitting messages through voice and messaging channels is also described. | 03-11-2010 |
20100332393 | ONLINE PAYER AUTHENTICATION SERVICE - A payment authentication service authenticates the identity of a payer during online transactions. The authentication service of the present invention allows a card issuer to verify a cardholder's identity using a variety of authentication methods, such as the use of passwords. Also, the only system participant requiring a certificate is the issuing financial institution. One embodiment of the invention for authenticating the identity of a cardholder during an online transaction involves querying an access control server to determine if a cardholder is enrolled in the payment authentication service, requests a password from the cardholder, verifies the password, and notifies a merchant whether the cardholder's authenticity has been verified. In another aspect of the invention, a chip card and the authentication service independently generate cryptograms that must match in order for the service to verify that the correct chip card is being used by the cardholder. | 12-30-2010 |
20120066129 | DATA AUTHENTICATION AND PROVISIONING METHOD AND SYSTEM - Techniques for authenticating the identity and validating the profile of an individual (“a presenter”) who presents him or herself to another party (“an acceptor”) as having a certain identity and having certain corresponding profile data are described. The invention can be advantageously used in Internet transactions where such authentication and validation is difficult to perform. The techniques of the present invention allow the trusted party to give a definitive answer regarding the authentication of identity and validity of profile data. Other services such as profile data provisioning and profile data updating can also be performed. | 03-15-2012 |
20120066130 | DATA AUTHENTICATION AND PROVISIONING METHOD AND SYSTEM - Techniques for authenticating the identity and validating the profile of an individual (“a presenter”) who presents him or herself to another party (“an acceptor”) as having a certain identity and having certain corresponding profile data are described. The invention can be advantageously used in Internet transactions where such authentication and validation is difficult to perform. The techniques of the present invention allow the trusted party to give a definitive answer regarding the authentication of identity and validity of profile data. Other services such as profile data provisioning and profile data updating can also be performed. | 03-15-2012 |
20120323734 | ONLINE ACCOUNT AUTHENTICATION SERVICE - A payment authentication service authenticates the identity of a payer during online transactions. The authentication service allows a card issuer to verify a cardholder's identity using a variety of authentication methods, such as the use of passwords. Also, the only system participant requiring a certificate is the issuing financial institution. Authenticating the identity of a cardholder during an online transaction involves querying an access control server to determine if a cardholder is enrolled in the payment authentication service, requesting a password from the cardholder, verifying the password, and notifying a merchant whether the cardholder's authenticity has been verified. A chip card and the authentication service independently generate cryptograms to match in order for the service to verify that the correct chip card is being used by the cardholder. | 12-20-2012 |
20130317989 | Method and System for Performing Two Factor Authentication in Mail Order and Telephone Order Transactions - The method for authenticating a mail order or telephone order transaction according to the present invention includes receiving authentication information from a cardholder, providing authentication information to an issuer, and determining whether the authentication information is valid. If the authentication information is valid, the issuer informs the merchant that the transaction is valid. In an embodiment, the issuer may not supply a personal assurance message and/or other confidential cardholder information previously supplied by the cardholder in response to the authentication information. | 11-28-2013 |
20150348023 | METHODS AND SYSTEMS FOR PERFORMING AUTHENTICATION IN CONSUMER TRANSACTIONS - The method for authenticating a mail order or telephone order transaction according to the present invention includes receiving authentication information from a cardholder, providing authentication information to an issuer, and determining whether the authentication information is valid. If the authentication information is valid, the issuer informs the merchant that the transaction is valid. In an embodiment, the issuer may not supply a personal assurance message and/or other confidential cardholder information previously supplied by the cardholder in response to the authentication information. | 12-03-2015 |
Patent application number | Description | Published |
20080312232 | Substituted amide derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 12-18-2008 |
20090149468 | Substituted heterocyclic compounds and methods of use - The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T-cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs. | 06-11-2009 |
20090181943 | Inhibitors of Histone Deacetylase - This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I) | 07-16-2009 |
20090270445 | Thiazole compounds and methods of use - The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein. | 10-29-2009 |
20090275592 | Heterocyclic modulators of PKB - The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. | 11-05-2009 |
20090298836 | Thiadiazole modulators of PKB - The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. | 12-03-2009 |
20110118252 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 05-19-2011 |
20110183957 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 07-28-2011 |
20110230428 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 09-22-2011 |
20120065185 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE - Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. | 03-15-2012 |
20120070413 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 03-22-2012 |
20120302539 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents. | 11-29-2012 |
20130029988 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 01-31-2013 |
20130116216 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents. | 05-09-2013 |
20130273004 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE - Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. | 10-17-2013 |
20130331370 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 12-12-2013 |
20140163009 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 06-12-2014 |
20140329795 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 11-06-2014 |
20140329816 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 11-06-2014 |
20150057238 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 02-26-2015 |
20150203468 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 07-23-2015 |
20150232420 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents. | 08-20-2015 |
20160024019 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 01-28-2016 |
20160031863 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 02-04-2016 |
20160031876 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 02-04-2016 |
20160039745 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 02-11-2016 |
Patent application number | Description | Published |
20110059779 | Power Management Of A Radio Data Transceiver - Methods and apparatuses for operating a wireless mobile station configured to communicate with a wireless access point are described. A first awake timer may be started in response to receiving a beacon signal from the wireless access point. The beacon signal may indicate that data is available or pending for the wireless mobile station. A second awake timer may be started in response to data received from the wireless access point. When the second awake timer expires, the wireless mobile station may return to the sleep state. In one embodiment, the first awake timer counts for a first period of time and the second awake timer counts for a second period of time which is shorter than the first period of time. The RF radio may be in a higher power state when the first and/or the second awake timers are counting. In one embodiment, the wireless mobile station and the wireless access points may be synchronized using target beacon transmission times of the beacon signal. | 03-10-2011 |
20110153773 | EFFICIENT SERVICE ADVERTISEMENT AND DISCOVERY IN A PEER-TO-PEER NETWORKING ENVIRONMENT WITH COOPERATIVE ADVERTISEMENT - Operating conditions of a remote device and operating conditions of a local device are compared, where the local device and the remote device are located within a predetermined proximity of a wireless network. An advertisement request is transmitted from the local device to the remote device based on the comparison of the operating conditions of the local device and the remote device. The advertisement request includes information identifying one or more services advertised by the local device, whereby the remote device is configured to advertise the one or more services on behalf of the local device in the wireless network. | 06-23-2011 |
20110153789 | EFFICIENT SERVICE ADVERTISEMENT AND DISCOVERY IN A PEER-TO-PEER NETWORKING ENVIRONMENT WITH DYNAMIC ADVERTISEMENT AND DISCOVERY PERIODS BASED ON OPERATING CONDITIONS - A local device is configured to monitor operating conditions coupled to a wireless network. An advertisement period is dynamically adjusted based on the operating conditions of the local device, where the advertisement period is dynamically adjusted based on at least one of a battery condition of the local device, a user behavior of the local device, network traffic condition, and a type of service to be advertised. The local device broadcasts a service advertisement in the wireless network according to the adjusted advertisement period, the service advertisement including one or more service IDs for identifying one or more services to be advertised from the local device. | 06-23-2011 |
20110153818 | EFFICIENT SERVICE ADVERTISEMENT AND DISCOVERY IN MULTIPLE WIRELESS NETWORKS - A local device broadcasts a first advertisement in a first wireless network via a first wireless interface, where the first advertisement includes one or more service identifiers (IDs) identifying one or more services being advertised and an availability schedule of the local device in the first wireless network. The local device broadcasts a second advertisement in a second wireless network via a second wireless interface. The local device scans in the first wireless network during an availability window of the availability schedule for a response to the first advertisement, where the broadcast of the second advertisement is disabled during the availability window. | 06-23-2011 |
20110154084 | EFFICIENT SERVICE ADVERTISEMENT AND DISCOVERY IN A PEER-TO-PEER NETWORKING ENVIRONMENT - A local device broadcasts a service advertisement in a wireless network, where the service advertisement includes one or more service identifiers (IDs) identifying one or more services being advertised and an availability schedule of the local device. Optionally, the local device reduces power to at least a portion of the local device and wakes up at a time according to the availability schedule. The local device listens in the wireless network according to the availability schedule of the local device. In response to a service request received from a remote device during the availability window, the local device transmits a service response to the remote device. The service request includes one or more service IDs identifying one or more services being inquired by the remote device and the service response includes detailed information associated with one or more services identified by the one or more service IDs. | 06-23-2011 |
20120117400 | EFFICIENT SERVICE ADVERTISEMENT AND DISCOVERY IN A PEER-TO-PEER NETWORKING ENVIRONMENT - A local device broadcasts a service advertisement in a wireless network, where the service advertisement includes one or more service identifiers (IDs) identifying one or more services being advertised and an availability schedule of the local device. Optionally, the local device reduces power to at least a portion of the local device and wakes up at a time according to the availability schedule. The local device listens in the wireless network according to the availability schedule of the local device. In response to a service request received from a remote device during the availability window, the local device transmits a service response to the remote device. The service request includes one or more service IDs identifying one or more services being inquired by the remote device and the service response includes detailed information associated with one or more services identified by the one or more service IDs. | 05-10-2012 |
20130122971 | POWER MANAGEMENT OF A RADIO DATA TRANSCEIVER - Methods and apparatuses for operating a wireless mobile station configured to communicate with a wireless access point are described. A first awake timer may be started in response to receiving a beacon signal from the wireless access point. The beacon signal may indicate that data is available or pending for the wireless mobile station. A second awake timer may be started in response to data received from the wireless access point. When the second awake timer expires, the wireless mobile station may return to the sleep state. In one embodiment, the first awake timer counts for a first period of time and the second awake timer counts for a second period of time which is shorter than the first period of time. The RF radio may be in a higher power state when the first and/or the second awake timers are counting. In one embodiment, the wireless mobile station and the wireless access points may be synchronized using target beacon transmission times of the beacon signal. | 05-16-2013 |
20140059369 | EFFICIENT SERVICE ADVERTISEMENT AND DISCOVERY IN A PEER-TO-PEER NETWORKING ENVIRONMENT - A local device broadcasts a service advertisement in a wireless network, where the service advertisement includes one or more service identifiers (IDs) identifying one or more services being advertised and an availability schedule of the local device. Optionally, the local device reduces power to at least a portion of the local device and wakes up at a time according to the availability schedule. The local device listens in the wireless network according to the availability schedule of the local device. In response to a service request received from a remote device during the availability window, the local device transmits a service response to the remote device. The service request includes one or more service IDs identifying one or more services being inquired by the remote device and the service response includes detailed information associated with one or more services identified by the one or more service IDs. | 02-27-2014 |
20150215864 | POWER MANAGEMENT OF A RADIO DATA TRANSCEIVER - Methods and apparatuses for operating a wireless mobile station configured to communicate with a wireless access point are described. A first awake timer may be started in response to receiving a beacon signal from the wireless access point. The beacon signal may indicate that data is available or pending for the wireless mobile station. A second awake timer may be started in response to data received from the wireless access point. When the second awake timer expires, the wireless mobile station may return to the sleep state. In one embodiment, the first awake timer counts for a first period of time and the second awake timer counts for a second period of time which is shorter than the first period of time. The RF radio may be in a higher power state when the first and/or the second awake timers are counting. In one embodiment, the wireless mobile station and the wireless access points may be synchronized using target beacon transmission times of the beacon signal. | 07-30-2015 |
Patent application number | Description | Published |
20120089170 | INTRAGASTRIC BALLOON GEOMETRIES - The present application provides intragastric devices for the treatment of obesity. The intragastric devices advantageously act as a volume-occupying device, and is able to survive implantation in a patient's stomach for a year or longer. In addition, the intragastric devices may provide additional benefits. For example, the intragastric device may be configured to stimulate an inner stomach wall and/or temporarily block the pylorus to slow gastric emptying and/or be rotationally variant, thereby encouraging different stimulation points on the inner wall of the stomach and limiting the stomach's ability to adapt over long term implantation. | 04-12-2012 |
20120089172 | RE-SHAPING INTRAGASTRIC IMPLANTS - The present application provides implantable intragastric devices for the treatment of obesity. The intragastric devices advantageously act as a volume-occupying device, and is able to survive implantation in a patient's stomach for a year or longer. In addition, the intragastric devices may be configured to stimulate an inner stomach wall and/or temporarily block the pylorus to slow gastric emptying and/or be rotationally variant, thereby encouraging different stimulation points on the inner wall of the stomach and limiting the stomach's ability to adapt over long term implantation. The intragastric devices may reshape the stomach cavity, such as by pushing on opposite sides so as to “planarize” the stomach. For instance, the device may be an inflated disk, or an implantable loop or a springy coil that may be straightened for delivery/extraction yet assume the loop or coil shape upon implant. | 04-12-2012 |
20120095384 | STOMACH-SPANNING GASTRIC IMPLANTS - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety. The implants may take up volume within the stomach, thus reducing the digestive capacity. Additionally, the implants may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, a number of implants slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. Other implants delay digestion by providing a duodenal sleeve. A number of implants combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the implants within a delivery tube and transorally advancing the implants through the esophagus to be deployed within the stomach. Removal of the implants occurs in the reverse. | 04-19-2012 |
20120095385 | INTRAGASTRIC IMPLANTS WITH DUODENAL ANCHORS - Intragastric fluid transfer devices and related methods for operation thereof are disclosed. The intragastric fluid transfer devices and related methods are intended to assist a patient in maintaining a healthy body weight by stimulating the inner stomach walls and/or the inner duodenum walls. Features of the intragastric fluid transfer device include insertion of the devices transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these intragastric fluid transfer devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. | 04-19-2012 |
20120095483 | ANCHORED NON-PIERCING DUODENAL SLEEVE AND DELIVERY SYSTEMS - An intragastric implant for obesity treatment is disclosed. The device delays digestion by providing a duodenal sleeve, and may also slows gastric emptying by limiting flow through the pyloric sphincter. The implant includes an elongated axially-compressible duodenal sleeve having a non-tissue-piercing anchor on a proximal end sized to lodge within the duodenal bulb. The anchor may have oppositely-directed anchoring flanges to resists migration in both directions. The sleeve may also have barbed ribs to resist proximal movement back up into the stomach. A method of implant includes collapsing/compressing the device and transorally advancing it through the esophagus to be deployed within the duodenum. A dissolvable jacket may constrain the implant for delivery and naturally dissolve upon implant. Removal of the implant may occur in the reverse. | 04-19-2012 |
20120095494 | INTRAGASTRIC IMPLANTS WITH COLLAPSIBLE FRAMES - Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and/or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight. Features of the devices include insertion transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. The devices have the capacity to vary in size and are desirably self-actuating in that they change shape and/or volume using internal motors or actuators. The changing character of the devices helps prevent the person's stomach from compensating for the implant, such as sometimes happens with static intragastric devices. | 04-19-2012 |
20120095495 | SPACE-FILLING INTRAGASTRIC IMPLANTS WITH FLUID FLOW - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, certain devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. | 04-19-2012 |
20120095496 | REACTIVE INTRAGASTRIC IMPLANT DEVICES - Transoral three-dimensionally orthogonal intragastric spring systems, devices, methods of operation and manufacture are provided. A transoral three-dimensionally orthogonal intragastric spring system and/or device (and related methods of manufacture and operation) may reduce obesity or weight by stimulating the stomach walls of the patient. The three-dimensionally orthogonal intragastric spring device may be a purely mechanical device comprising a flexible body which in response to an input force in one direction, may deform and cause a resultant displacement in an orthogonal direction, thereby exerting a pressure on the inner stomach walls of the patient. Alternatively, a three-dimensionally orthogonal intragastric spring device may include a variable size balloon configured to occupy volume in the patient's stomach, thereby reducing the amount of space in the patient's stomach. | 04-19-2012 |
20120095497 | NON-INFLATABLE GASTRIC IMPLANTS AND SYSTEMS - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, or the greater and lesser curvatures in the middle of the stomach, to stimulate satiety-inducing nerves. Some devices may combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. | 04-19-2012 |
20120095499 | UPPER STOMACH GASTRIC IMPLANTS - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach | 04-19-2012 |
20120191125 | INTRAGASTRIC IMPLANTS WITH MULTIPLE FLUID CHAMBERS - An intragastric obesity treatment implant promotes a feeling of satiety in the patient by contacting the insides of the stomach wall, reducing the space in the stomach, or otherwise reducing the amount of food consumed. One intragastric obesity treatment implant two inflatable balloons coupled via a flow restrictor through which fluid may flow in response to peristaltic motions of a patient's stomach. Additionally, one implant comprises a pumping chamber coupled to a reservoir, where the pumping chamber moves stomach fluids into the reservoir in response to peristaltic motions of the patient's stomach. | 07-26-2012 |
20130035711 | INTRAGASTRIC BALLOON FOR TREATING OBESITY - A transorally implanted intragastric balloon or treating obesity and for weight control including a variable size balloon with one or interconnected regions acting to exert a pressure on the stomach, to provide a stomach volume occupying effect, and/or to anchor the balloon within the stomach. | 02-07-2013 |
20130131632 | INJECTION DEVICE AND METHOD FOR DILUTING AN INJECTABLE FLUID - An injection device enables a user to control the dilution ratio of mixed injectable fluid. In one embodiment, the injection device includes a drive unit configured to apply extrusion forces to fluids. In one embodiment, the injection device produces the mixed injectable fluid based on a selected dilution ratio. In one embodiment, the injection device produces the mixed injectable fluid based on selected injection rates. | 05-23-2013 |
20130131633 | MODULAR INJECTION SYSTEM AND METHOD FOR DILUTING AN INJECTABLE FLUID - A modular injection system enables a user to control the dilution ratio of mixed injectable fluid. In one embodiment, modular injection system includes a handheld injection device operatively connected to a separate control device. In one embodiment, the control device includes a drive unit configured to apply extrusion forces to fluids. In another embodiment, the handheld injection device includes the drive unit. In one embodiment, the modular injection system produces the mixed injectable fluid based on a selected dilution ratio. In one embodiment, the modular injection system produces the mixed injectable fluid based on selected injection rates. | 05-23-2013 |
20130289466 | STOMACH-SPANNING GASTRIC IMPLANTS - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety. The implants may take up volume within the stomach, thus reducing the digestive capacity. Additionally, the implants may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, a number of implants slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. Other implants delay digestion by providing a duodenal sleeve. A number of implants combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the implants within a delivery tube and transorally advancing the implants through the esophagus to be deployed within the stomach. Removal of the implants occurs in the reverse. | 10-31-2013 |
20130296765 | INTRAGASTRIC IMPLANTS WITH DUODENAL ANCHORS - Intragastric fluid transfer devices and related methods for operation thereof are disclosed. The intragastric fluid transfer devices and related methods are intended to assist a patient in maintaining a healthy body weight by stimulating the inner stomach walls and/or the inner duodenum walls. Features of the intragastric fluid transfer device include insertion of the devices transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these intragastric fluid transfer devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. | 11-07-2013 |
20130331643 | SELF-ADJUSTING GASTRIC BAND - Generally described herein are automatic, self-adjusting, gastric banding systems and improvements thereof, that are capable of automatically relaxing and contracting in response to a large bolus passing through the area of a patient's stomach constricted by a gastric band. Alternatively, and/or in addition in one or more embodiments, the gastric banding systems described herein may also help prevent pouch dilatation and/or erosion. The apparatus and systems described herein aid in facilitating obesity control and/or treating obesity-related diseases while generally being non-invasive once implanted. Furthermore, certain embodiments of the self-adjusting gastric banding systems disclosed herein are automatically adjustable without complicated fluid control mechanisms, flow rate limiting devices, and/or valves. The automatic adjustments may also be made in response to other changes in the patient's esophageal-gastric junction, for example, in response to size, shape, and or location changes. | 12-12-2013 |
20140025100 | RE-SHAPING INTRAGASTRIC IMPLANTS - The present application provides implantable intragastric devices for the treatment of obesity. The intragastric devices advantageously act as a volume-occupying device, and is able to survive implantation in a patient's stomach for a year or longer. In addition, the intragastric devices may be configured to stimulate an inner stomach wall and/or temporarily block the pylorus to slow gastric emptying and/or be rotationally variant, thereby encouraging different stimulation points on the inner wall of the stomach and limiting the stomach's ability to adapt over long term implantation. The intragastric devices may reshape the stomach cavity, such as by pushing on opposite sides so as to “planarize” the stomach. For instance, the device may be an inflated disk, or an implantable loop or a springy coil that may be straightened for delivery/extraction yet assume the loop or coil shape upon implant. | 01-23-2014 |
20140066845 | INJECTION DEVICE HAVING AN ANGLED TIP PORTION - In one embodiment, the handheld injection device includes a first housing having a first axis and a second housing having a second axis. In one embodiment, the second housing is configured to support a needle. In one embodiment, the first axis and a second axis form an adjustable angle between about 180 degrees and about 90 degrees. | 03-06-2014 |
20140350516 | MECHANICAL SYRINGE ACCESSORY - Described herein are syringe accessories that can be attached to standard syringes. These accessories utilize one or more mechanisms that can provide at least one additional sensory feedback to the user when performing an aliquot or dosed injection. In other embodiments, the accessories can prevent overdosing. | 11-27-2014 |
20150093362 | FAT PROCESSING SYSTEM - Methods and devices for treating lipoaspirate for use in fat grafting procedures are provided and generally include a canister for containing lipoaspirate, a separation mechanism structured to separate both oils and other materials from cellular components of lipoaspirate contained in the canister. The separation mechanism includes filters having different filtering capacities, for example, different pore sizes. | 04-02-2015 |
20150094753 | Intragastric Implants with Collapsible Frames - Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and/or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight. Features of the devices include insertion transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. The devices have the capacity to vary in size and are desirably self-actuating in that they change shape and/or volume using internal motors or actuators. The changing character of the devices helps prevent the person's stomach from compensating for the implant, such as sometimes happens with static intragastric devices. | 04-02-2015 |
20150126929 | DERMAL FILLER INJECTOR - A dermal filler injector is provided which includes a handpiece and a coupling mechanism for operationally coupling the handpiece with a dermal filler cartridge. The handpiece includes a motor for controllably driving a plunger in the cartridge to provide effective and controlled injection of a dermal filler into skin. | 05-07-2015 |
20150150700 | Reactive Intragastric Implant Devices - Transoral implantable devices includes an inflatable body made of a material that permits it to be compressed into a substantially linear transoral delivery configuration and that when implanted in the stomach is adapted to reduce obesity or weight by stimulating the stomach walls of the patient. The body has a plurality of popout features on its surface that reside generally flush with the inflatable body in relaxed, refracted states, and which respond to an increase in pressure within the inflatable body by projecting outward from the body in a stressed, deployed state. The popout features may convert between their retracted and deployed states by movement of rolling diaphragms formed in the inflatable body. | 06-04-2015 |
20150327986 | TEXTURED BREAST IMPLANT AND METHODS OF MAKING SAME - Methods for texturing surgical implants, for example, breast implants, are provided. The methods include the use of computer controlled 3D printing of a sacrificial material to create a textured surface on an unfinished surface of the implant. | 11-19-2015 |
20150328405 | HIGH FORCE INJECTION DEVICES - Described herein are assisted syringes. The syringes provide a higher force to the plunger tip than the extrusion force applied to the plunger. The assisted syringes can be used to inject or extrude viscous materials. | 11-19-2015 |
20150343147 | INJECTION DEVICE - Disclosed herein are devices and methods that can provide assistance with extruding and/or aspirating high viscosity materials such as dermal fillers. | 12-03-2015 |
20160022460 | Endolumenal Esophageal Restriction Device - Generally described herein are apparatus, systems and methods related to a novel esophageal device implantable in the patient's body and designed to replicate the restrictive and satiety mechanism associated with gastric banding systems known in the art. The device can be a compliant and tubular-shaped and fixated within the gastro-esophageal lumen using tissue anchors. | 01-28-2016 |
20160095984 | DEVICES FOR INJECTION AND DOSING - Injection devices are provided which include a handpiece capable of housing a cartridge containing an injectable composition, and a head coupled to the handpiece and housing a plurality of retractable needles and a dosing mechanism. Methods of treating skin surfaces are also provided. | 04-07-2016 |
Patent application number | Description | Published |
20120088962 | SELF-ADJUSTING GASTRIC BAND - Generally described herein are automatic, self-adjusting, gastric banding systems and improvements thereof, that are capable of automatically relaxing and contracting in response to a large bolus passing through the area of a patient's stomach constricted by a gastric band. Alternatively, and/or in addition in one or more embodiments, the gastric banding systems described herein may also help prevent pouch dilatation and/or erosion. The apparatus and systems described herein aid in facilitating obesity control and/or treating obesity-related diseases while generally being non-invasive once implanted. Furthermore, certain embodiments of the self-adjusting gastric banding systems disclosed herein are automatically adjustable without complicated fluid control mechanisms, flow rate limiting devices, and/or valves. The automatic adjustments may also be made in response to other changes in the patient's esophageal-gastric junction, for example, in response to size, shape, and or location changes. | 04-12-2012 |
20120095288 | SELF-ADJUSTING GASTRIC BAND - Generally described herein are automatic, self-adjusting, gastric banding systems and improvements thereof, that are capable of automatically relaxing and contracting in response to a large bolus passing through the area of a patient's stomach constricted by a gastric band. Alternatively, and/or in addition in one or more embodiments, the gastric banding systems described herein may also help prevent pouch dilatation and/or erosion. The apparatus and systems described herein aid in facilitating obesity control and/or treating obesity-related diseases while generally being non-invasive once implanted. Furthermore, certain embodiments of the self-adjusting gastric banding systems disclosed herein are automatically adjustable without complicated fluid control mechanisms, flow rate limiting devices, and/or valves. The automatic adjustments may also be made in response to other changes in the patient's esophageal-gastric junction, for example, in response to size, shape, and or location changes. | 04-19-2012 |
20120095484 | ARTICULATED GASTRIC IMPLANT CLIP - Intragastric implant devices for obesity treatment are disclosed. The device is passive and does not autonomously change shape, but instead reacts to movement of the stomach to induce satiety. The device includes a series of connected, articulated clips that plicate the stomach wall nondestructively (no puncturing through the gastric wall) such that the overall volume of the stomach is reduced. Cam-shaped clamping surfaces prevent slippage of the stomach tissue from within the clips. Methods of implant are disclosed including delivering the device through a transoral delivery tube and advancing the device through the esophagus to be deployed within the stomach. Removal of the device occurs in the reverse. | 04-19-2012 |
20130102840 | IMPLANTABLE INJECTION PORT - Injection ports are disclosed for use with a gastric band for the treatment of obesity. An injection port may include a septum having a top surface, a bottom surface, and a side wall connecting the top surface to the bottom surface. The injection port may also include a housing including a first inner side wall being tapered inwards such that an opening defined at a first end is larger than an opening defined at a second end, the tapering of the first inner side wall being used to secure the septum within the housing. The housing may further include a second inner side wall having a first end and a second end, the first end of the second inner side wall joined to the second end of the first inner side wall, and a bottom surface joined to the second end of the second inner side wall. | 04-25-2013 |
20130131589 | INJECTION DEVICE HAVING AN ANGLED TIP PORTION - In one embodiment, the handheld injection device includes a first housing having a first axis and a second housing having a second axis. In one embodiment, the second housing is configured to support a needle. In one embodiment, the first axis and a second axis form an adjustable angle between about 180 degrees and about 90 degrees. | 05-23-2013 |
20130190557 | GASTRIC BANDS FOR REDUCING OBSTRUCTIONS - Generally described herein are apparatus, systems and methods related to gastric bands which provide increased compliance to reduce food obstructions and/or reduces over restriction causing symptoms such as gastric enlargement and pouch dilatation. In one embodiment, a dual ringed reservoir band or inflatable portion is provided. In one embodiment, an additional ring or a middle pouch may be added to the dual ringed reservoir band. The addition of an additional ring or middle pouch may further increase band compliance resulting in even fewer food obstructions. In another embodiment, one or more funnels can also be implemented into a gastric banding system to induce satiety and/or for guiding a bolus through the gastric band. | 07-25-2013 |
20130190892 | ENDOLUMENAL ESOPHAGEAL RESTRICTION DEVICE - Generally described herein are apparatus, systems and methods related to a novel esophageal device implantable in the patient's body and designed to replicate the restrictive and satiety mechanism associated with gastric banding systems known in the art. The device can be a compliant and tubular-shaped and fixated within the gastro-esophageal lumen using tissue anchors. | 07-25-2013 |
20130211440 | ENDOSCOPIC TOOLS FOR THE REMOVAL OF BALLOON-LIKE INTRAGASTRIC DEVICES - A mechanism for removing a fluid-filled object such as an intragastric balloon from a patient. The apparatus includes a delivery tube having a lumen and a retrieval tool able to slide within the lumen that can both puncture and grasp the intragastric balloon. The retrieval tool may have sharpened graspers with either a sharp tip and/or knife-like edges. Alternatively, the delivery tube itself may have sharpened cutting blades that deploy outward to puncture the intragastric balloon. One embodiment utilizes a suction cup tip on the delivery sheath and a sharpened puncture rod that extends past the distal tip of the lumen, for rapid deflation of a balloon. Various embodiments hasten the deflation process and simplify the manipulation required by the surgeon. | 08-15-2013 |
20130281911 | ANCHORED NON-PIERCING DUODENAL SLEEVE AND DELIVERY SYSTEMS - An intragastric implant for obesity treatment is disclosed. The device delays digestion by providing a duodenal sleeve, and may also slows gastric emptying by limiting flow through the pyloric sphincter. The implant includes an elongated axially-compressible duodenal sleeve having a non-tissue-piercing anchor on a proximal end sized to lodge within the duodenal bulb. The anchor may have oppositely-directed anchoring flanges to resists migration in both directions. The sleeve may also have barbed ribs to resist proximal movement back up into the stomach. A method of implant includes collapsing/compressing the device and transorally advancing it through the esophagus to be deployed within the duodenum. A dissolvable jacket may constrain the implant for delivery and naturally dissolve upon implant. Removal of the implant may occur in the reverse. | 10-24-2013 |
20140180327 | Endoscopic Tools for the Removal of Balloon-Like Intragastric Devices - A mechanism for removing a fluid-filled object such as an intragastric balloon from a patient. The apparatus includes a delivery tube having a lumen and a retrieval tool able to slide within the lumen that can both puncture and grasp the intragastric balloon. The retrieval tool may have sharpened graspers with either a sharp tip and/or knife-like edges. Alternatively, the delivery tube itself may have sharpened cutting blades that deploy outward to puncture the intragastric balloon. One embodiment utilizes a suction cup tip on the delivery sheath and a sharpened puncture rod that extends past the distal tip of the lumen, for rapid deflation of a balloon. Various embodiments hasten the deflation process and simplify the manipulation required by the surgeon. | 06-26-2014 |
20140350517 | INJECTION DEVICE WITH STRESS PROTECTION - Described are devices and systems for protection of injectable substances such as adipose cells from excessive stress or pressure during injection procedures. Further described are stress control mechanisms for detecting and/or controlling stress or pressure within injection devices. | 11-27-2014 |
20150142044 | Non-Inflatable Gastric Implants and Systems - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, or the greater and lesser curvatures in the middle of the stomach, to stimulate satiety-inducing nerves. Some devices may combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. | 05-21-2015 |
20150209169 | Space-Filling Intragastric Implants with Fluid Flow - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, certain devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. | 07-30-2015 |
20150223957 | Endoscopic Tools for the Removal of Balloon-Like Intragastric Devices - A mechanism for removing a fluid-filled object such as an intragastric balloon from a patient. The apparatus includes a delivery tube having a lumen and a retrieval tool able to slide within the lumen that can both puncture and grasp the intragastric balloon. The retrieval tool may have sharpened graspers with either a sharp tip and/or knife-like edges. Alternatively, the delivery tube itself may have sharpened cutting blades that deploy outward to puncture the intragastric balloon. One embodiment utilizes a suction cup tip on the delivery sheath and a sharpened puncture rod that extends past the distal tip of the lumen, for rapid deflation of a balloon. Various embodiments hasten the deflation process and simplify the manipulation required by the surgeon. | 08-13-2015 |
20150272761 | Intragastric Balloon for Treating Obesity - A transorally implanted intragastric balloon or treating obesity and for weight control including a variable size balloon with one or interconnected regions acting to exert a pressure on the stomach, to provide a stomach volume occupying effect, and/or to anchor the balloon within the stomach. | 10-01-2015 |
20160030219 | Upper Stomach Gastric Implants - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach | 02-04-2016 |